Woof Gang Achieves Record Growth in 2025

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) — Woof Gang Bakery & Grooming (“Woof Gang” or “the Company”), the neighborhood pet grooming and treat boutique, today announced record-breaking results for 2025, reaching $150m in system wide sales, a 25% YoY increase. The sales reflect a year of significant growth across strategic regions in the Midwest, Northeast, […]

Anika Therapeutics Announces Leadership Transition

(NASDAQ:ANIK), Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive Officer Cheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

(NASDAQ:LAB), BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million.

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights GlobeNewswire January 08, 2026 Preliminary Q4 2025 PEMGARDA(R) (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025

ONAR Completes Sale of Certain Legacy Assets in a Secured $1.5 Million Seller-Financed Transaction

(Other OTC:ONAR),(OTC US:ONAR), Miami, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) — ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform that acquires and scales specialist agencies, today announced that its subsidiary, ONAR, LLC, completed the sale of substantially all of the assets of VMED Services, LLC, which conducted operations under the

The Simply Good Foods Company Reports Fiscal First Quarter 2026 Financial Results and Reaffirms Fiscal Year 2026 Outlook

(NASDAQ:SMPL),(NASDAQ:SMPL.W), DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported financial results for the thirteen weeks ended November 29, 2025. First Quarter Summary:(1) Net sales of $340.2 million versus $341.3 million Net income of $25.3

Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers

Microchip Releases Custom Firmware For NVIDIA DGX Spark For Its MEC1723 Embedded Controllers Solution delivers secure boot, power management and system control for complex computing GlobeNewswire January 08, 2026 CHANDLER, Ariz., Jan. 08, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) has announced the release of custom-designed firmware for its MEC1723 Embedded Controller (EC), specifically

Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 8:00 am Pacific Time. About Transpire Bio Inc.Transpire Bio Inc. is an integrated, US-based, revenue-generating, clinical-stage

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

(NasdaqGM:CLYM), First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

(NASDAQ:AVIR), Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of

Scroll to Top